IL17RB

Summary

IL17RB (interleukin 17 receptor B, HGNC:18015) is a protein-coding gene on chromosome 3p21.1, encoding Interleukin-17 receptor B (Q9NRM6). Receptor for the pro-inflammatory cytokines IL17B and IL17E.

The protein encoded by this gene is a cytokine receptor. This receptor specifically binds to IL17B and IL17E, but does not bind to IL17 and IL17C. This receptor has been shown to mediate the activation of NF-kappaB and the production of IL8 induced by IL17E. The expression of the rat counterpart of this gene was found to be significantly up-regulated during intestinal inflammation, which suggested the immunoregulatory activity of this receptor.

Source: NCBI Gene 55540 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 56 total
• MANE Select transcript: NM_018725

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18015
Approved symbol	IL17RB
Name	interleukin 17 receptor B
Location	3p21.1
Locus type	gene with protein product
Status	Approved
Aliases	IL17RH1, EVI27, CRL4
Ensembl gene	ENSG00000056736
Ensembl biotype	protein_coding
OMIM	605458
Entrez	55540

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 15 protein_coding, 1 retained_intron

ENST00000288167, ENST00000475124, ENST00000494338, ENST00000899722, ENST00000899723, ENST00000899724, ENST00000899725, ENST00000899726, ENST00000899727, ENST00000899728, ENST00000899729, ENST00000899730, ENST00000899731, ENST00000899732, ENST00000912107, ENST00000963738

RefSeq mRNA: 1 — MANE Select: NM_018725 NM_018725

CCDS: CCDS2874

Canonical transcript exons

ENST00000288167 — 11 exons

Exon	Start	End
ENSE00001032480	53858719	53858818
ENSE00001128835	53864746	53865794
ENSE00001212759	53846568	53846648
ENSE00001212782	53857616	53857690
ENSE00003498270	53848664	53848688
ENSE00003535491	53849655	53849795
ENSE00003577603	53856844	53856986
ENSE00003604095	53855294	53855341
ENSE00003641176	53852871	53852997
ENSE00003656040	53860130	53860228
ENSE00003684062	53851999	53852126

Expression profiles

Bgee: expression breadth ubiquitous, 224 present calls, max score 93.56.

FANTOM5 (CAGE): breadth broad, TPM avg 5.6078 / max 724.6001, expressed in 664 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
36935	5.6078	664

Top tissues by expression

278 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
nephron tubule	UBERON:0001231	93.56	gold quality
adult mammalian kidney	UBERON:0000082	93.29	gold quality
kidney epithelium	UBERON:0004819	92.61	gold quality
right lobe of liver	UBERON:0001114	91.00	gold quality
kidney	UBERON:0002113	89.99	gold quality
ileal mucosa	UBERON:0000331	89.92	gold quality
right hemisphere of cerebellum	UBERON:0014890	89.58	gold quality
renal glomerulus	UBERON:0000074	89.17	gold quality
liver	UBERON:0002107	88.89	gold quality
amygdala	UBERON:0001876	88.83	gold quality
metanephros cortex	UBERON:0010533	88.83	gold quality
cerebellar hemisphere	UBERON:0002245	88.77	gold quality
cerebellar cortex	UBERON:0002129	88.67	gold quality
metanephric glomerulus	UBERON:0004736	88.47	gold quality
cerebellum	UBERON:0002037	88.17	gold quality
caudate nucleus	UBERON:0001873	88.00	gold quality
cortex of kidney	UBERON:0001225	87.92	gold quality
nucleus accumbens	UBERON:0001882	87.91	gold quality
anterior cingulate cortex	UBERON:0009835	87.07	gold quality
cingulate cortex	UBERON:0003027	87.01	gold quality
mucosa of transverse colon	UBERON:0004991	86.25	gold quality
putamen	UBERON:0001874	86.10	gold quality
rectum	UBERON:0001052	86.01	gold quality
temporal lobe	UBERON:0001871	86.00	gold quality
right frontal lobe	UBERON:0002810	85.96	gold quality
body of pancreas	UBERON:0001150	85.81	gold quality
substantia nigra	UBERON:0002038	85.51	gold quality
Brodmann (1909) area 9	UBERON:0013540	85.43	gold quality
colonic mucosa	UBERON:0000317	85.18	gold quality
hypothalamus	UBERON:0001898	85.13	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-GEOD-70580	yes	952.83
E-CURD-84	yes	346.87
E-ANND-3	yes	5.82
E-MTAB-8410	yes	5.46

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): MEIS2

Literature-anchored findings (GeneRIF, showing 40)

• The IL17RB protein expression increases during disease progression of breast cancer to hormonal therapy. (PMID:16609001)
• The IL17RB protein expression increases during disease progression of breast cancer to hormonal therapy. (PMID:16609019)
• HOXB13 and IL17BR has a role in progression of early-stage breast cancer (PMID:17008703)
• HOXB13 and IL17BR have roles in breast cancer (PMID:17453342)
• HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer (PMID:17975144)
• An index composed of inherited (CYP2D6) and tumor (HOXB13/IL17BR) gene variation identifies patients with varying degrees of resistance to tamoxifen. (PMID:18794098)
• Our results revealed that the IL-17RB +5661 G>A locus has a dominant and protective genetic effect on the development of asthma. (PMID:19118269)
• Increased expression of IL-17RB on allergen-challenged basophil is regulated by IL-3, inhibits apoptosis and promotes IgE-mediated degranulation of basophils (PMID:20545698)
• The present study identified upregulation of IL17RB during natural allergen exposure in patients with seasonal allergic rhinitis (SAR). (PMID:21252617)
• Results indicate that IL17RB may be the only gene expressed in CD4+ T cells whose transcript measurement is correlated with the variation in IgE level in asthmatics, but correlation between IL17RB and IgE was restricted to males only. (PMID:21473777)
• Allergen provocation induces functionally relevant, increased expression of IL-25 and its receptor in the asthmatic bronchial mucosa and dermis of sensitized atopic subjects. (PMID:21570719)
• In summary we established a new mechanism of IL17RB regulation-Smurf2 dependent degradation of its adaptor protein DAZAP2. (PMID:22070932)
• High IL17RB expression is associated with breast cancer. (PMID:23497539)
• Results show that amplified signaling of interleukin-17 receptor B (IL-17RB) and its ligand IL-17B promot tumorigenicity in breast cancer cells and impeded acinus formation in immortalized normal mammary epithelial cells. (PMID:23851503)
• The increased IL-25 levels in plasma and the expression of IL-17RA and IL-17RB on eosinophils in allergic asthma patients suggests that IL-25 may activate eosinophils during allergic inflammation. (PMID:24247484)
• IL-17RB has an essential role in pancreatic cancer growth, invasion, and metastasis. (PMID:25732306)
• Studies indicate that interleukin 17 (IL-17B)/interleukin 17 receptor B (IL-17RB) signaling is essential for pancreatic cancer malignancy. (PMID:26285835)
• The Breast Cancer Index (BCI) is a continuous risk index model of two previously described biomarkers: molecular grade index (MGI) and HOXB13:IL17BR (H:I) ratio (PMID:26728744)
• GS is acetylated at lysines 11 and 14, yielding a degron that is necessary and sufficient for binding and ubiquitylation by CRL4(CRBN) and degradation by the proteasome. (PMID:26990986)
• Therefore, IL-17E/IL-17RB signaling represents a potential therapeutic target for treatment of hepatocellular carcinoma (PMID:27000993)
• Our results identify a biochemical role for WDTC1 and extend the functional range of the CRL4 complex to the suppression of fat accumulation. (PMID:27113764)
• The results indicate that the IL-17B/IL-17RB signaling can promote the growth and migration of tumor cells. (PMID:27146881)
• collectively, this study uncovers a new role for CRL4CDT2 in protecting genomic integrity against replication stress via regulated proteolysis of PCNA-associated SDE2 and provides insights into how an integrated UBL domain within linear polypeptide sequence controls protein stability and function. (PMID:27906959)
• IL-17RB(+) granulocytes and T2M cells from peripheral blood were increased in subjects with asthma, and the 2 cell types correlated with degree of airflow obstruction. (PMID:27979026)
• Atopic IL-17RB(+) DCs can be up-regulated by LPS and promote a TH2-type response, implying that the IL-25/IL-17RB pathway may represent a potential molecular mechanism underlying the regulation of ECs on DCs in allergic airway disease. (PMID:28132739)
• This comprehensive review details the recognition of activity, signaling, and the roles of IL17B-IL17RB in breast cancer have caused to determination of new therapeutic mechanisms–{REVIEW} (PMID:28160754)
• IL-4 signaling up-regulates the IL-25 axis in human monocytic cells, and IL-25 may provide autocrine signals in monocytes and macrophages to sustain IL-17Rb expression and predispose to alternative activation. (PMID:28421819)
• IL-17RB can enhance thyroid cancer cell invasion and metastasis via ERK1/2 pathway-mediated MMP-9 expression, suggesting that IL-17RB may act as a potential therapeutic target for thyroid cancer therapy. (PMID:28715683)
• IL-17RB was up-regulated in lung cancer tissue and associated with lymph node metastasis and distant metastasis, as well as poor patient survival. 17RB activation is required for IL-17B-mediated ERK phosphorylation. (PMID:29496538)
• The expression of HOXB13, IL17BR, and mammaglobin 1 in sentinel lymph nodes predict the outcome of primary breast cancer patients. (PMID:29729704)
• As the ligase activity of CRL4Cdt2 depends on proliferating cell nuclear antigen (PCNA) loading onto DNA, the present results suggest that the DNA-binding domain facilitates the CRL4Cdt2-mediated recognition and ubiquitination of substrates bound to PCNA on chromatin. (PMID:30649446)
• Inflammation-dependent overexpression of c-Myc enhances CRL4(DCAF4) E3 ligase activity and promotes ubiquitination of ST7 in colitis-associated cancer. (PMID:30945288)
• Using CRISPR-Cas9-mediated IL17RB-CreERT2 knockin human organoids, study showed that IL17RB marks human colorectal cancer stem cells by lineage tracing, and that long-term targeting of IL17RB+ cells strongly suppressed the tumor growth in vivo. This study identifies IL17RB+ cancer stem cells and preclinically validates them as a cancer therapeutic target. (PMID:31182574)
• IL17RB predicts the prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer. (PMID:31585811)
• An IMiD-induced SALL4 degron system for selective degradation of target proteins. (PMID:32948804)
• Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses. (PMID:33455090)
• IL-17B/IL-17RB signaling cascade contributes to self-renewal and tumorigenesis of cancer stem cells by regulating Beclin-1 ubiquitination. (PMID:33649532)
• CRL4-DCAF12 Ubiquitin Ligase Controls MOV10 RNA Helicase during Spermatogenesis and T Cell Activation. (PMID:34065512)
• MEKK1-Dependent Activation of the CRL4 Complex Is Important for DNA Damage-Induced Degradation of p21 and DDB2 and Cell Survival. (PMID:34251884)
• IL-25 promotes trophoblast proliferation and invasion via binding with IL-17RB and associated with PE. (PMID:34264790)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	il17ra1a	ENSDARG00000058244
danio_rerio		ENSDARG00000070299
danio_rerio	il17ra2	ENSDARG00000100137
danio_rerio	il17ra1b	ENSDARG00000103208
mus_musculus	Il17rb	ENSMUSG00000015966
rattus_norvegicus	Il17rb	ENSRNOG00000015498
caenorhabditis_elegans		WBGENE00013415

Paralogs (4): IL17RD (ENSG00000144730), IL17RE (ENSG00000163701), IL17RC (ENSG00000163702), IL17RA (ENSG00000177663)

Protein

Protein identifiers

Interleukin-17 receptor B — Q9NRM6 (reviewed: Q9NRM6)

Alternative names: Cytokine receptor-like 4, IL-17 receptor homolog 1, Interleukin-17B receptor

All UniProt accessions (2): Q9NRM6, C9IZN0

UniProt curated annotations — full annotation on UniProt →

Function. Receptor for the pro-inflammatory cytokines IL17B and IL17E. May play a role in controlling the growth and/or differentiation of hematopoietic cells.

Subunit / interactions. Interacts with DAZAP2. Interacts with TRAF3IP2.

Subcellular location. Cell membrane Secreted.

Tissue specificity. Expressed in several endocrine tissues, mostly in fetal and adult liver, kidney, pancreas, testis, colon, brain and small intestine; not detected in peripheral blood leukocytes, lymphoid organs, and most cell lines.

Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9NRM6-1	1	yes
Q9NRM6-2	2

RefSeq proteins (1): NP_061195* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013568	SEFIR_dom	Domain
IPR032356	IL17R_A/B_N	Domain
IPR038683	IL17RA/B_FnIII-like_1_sf	Homologous_superfamily
IPR039465	IL-17_rcpt-like	Family
IPR043046	IL17RA/B_FnIII-like_2_sf	Homologous_superfamily

Pfam: PF08357, PF16556, PF16578

UniProt features (46 total): strand 18, sequence variant 7, glycosylation site 6, sequence conflict 4, splice variant 2, topological domain 2, helix 2, signal peptide 1, chain 1, transmembrane region 1, turn 1, domain 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
9OT1	ELECTRON MICROSCOPY	3
7UWJ	ELECTRON MICROSCOPY	3.2
7UWL	ELECTRON MICROSCOPY	3.7
7UWK	ELECTRON MICROSCOPY	4.4

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NRM6-F1	80.06	0.42

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (6): 197, 283, 67, 103, 156, 183

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-448424	Interleukin-17 signaling

MSigDB gene sets: 208 (showing top): GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_UP, BENPORATH_ES_WITH_H3K27ME3, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_INFLAMMATORY_RESPONSE, GOBP_RESPONSE_TO_PEPTIDE, PEREZ_TP63_TARGETS, GOBP_KERATINOCYTE_PROLIFERATION, GOBP_GROWTH, GOCC_CELL_SURFACE, GOBP_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_SUSTAINDED_IN_ERYTHROCYTE_UP, GOBP_POSITIVE_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_ERYTHROCYTE_UP, BILD_E2F3_ONCOGENIC_SIGNATURE, GOBP_REGULATION_OF_KERATINOCYTE_PROLIFERATION

GO Biological Process (6): regulation of cell growth (GO:0001558), defense response (GO:0006952), positive regulation of interleukin-13 production (GO:0032736), positive regulation of interleukin-5 production (GO:0032754), positive regulation of inflammatory response (GO:0050729), cytokine-mediated signaling pathway (GO:0019221)

GO Molecular Function (3): cytokine receptor activity (GO:0004896), interleukin-17 receptor activity (GO:0030368), protein binding (GO:0005515)

GO Cellular Component (5): extracellular region (GO:0005576), cytoplasm (GO:0005737), plasma membrane (GO:0005886), cell surface (GO:0009986), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Signaling by Interleukins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
positive regulation of cytokine production	2
cell growth	1
regulation of growth	1
regulation of cellular component organization	1
response to stress	1
interleukin-13 production	1
regulation of interleukin-13 production	1
interleukin-5 production	1
regulation of interleukin-5 production	1
inflammatory response	1
positive regulation of defense response	1
positive regulation of response to external stimulus	1
regulation of inflammatory response	1
cell surface receptor signaling pathway	1
cellular response to cytokine stimulus	1
transmembrane signaling receptor activity	1
cytokine-mediated signaling pathway	1
cytokine binding	1
immune receptor activity	1
cytokine receptor activity	1
interleukin-17 binding	1
binding	1
intracellular anatomical structure	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

1006 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IL17RB	IL17B	Q9UHF5	999
IL17RB	IL25	Q9H293	999
IL17RB	IL17C	Q9P0M4	993
IL17RB	IL17RA	Q96F46	988
IL17RB	IL17RE	Q8NFR9	986
IL17RB	IL17RC	Q8NAC3	973
IL17RB	IL17RD	Q8NFM7	959
IL17RB	IL17D	Q8TAD2	944
IL17RB	IL33	O95760	931
IL17RB	IL17F	Q96PD4	920
IL17RB	IL17A	Q16552	918
IL17RB	IL13	P35225	821
IL17RB	TSLP	Q969D9	802
IL17RB	HOXB13	Q92826	747
IL17RB	IL1RL1	Q01638	723

IntAct

16 interactions, top by confidence:

A	B	Type	Score
IL17RB	IL17RA	psi-mi:“MI:0403”(colocalization)	0.600
IL17RA	IL17RB	psi-mi:“MI:0407”(direct interaction)	0.600
IL17RB	IL25	psi-mi:“MI:0407”(direct interaction)	0.520
IL25	IL17RB	psi-mi:“MI:0407”(direct interaction)	0.520
IL17RB	DAZAP2	psi-mi:“MI:0915”(physical association)	0.510
IL17RA	IL25	psi-mi:“MI:0915”(physical association)	0.490
RPS6KA5	IL17RB	psi-mi:“MI:0915”(physical association)	0.370
IL17RB	RHOBTB3	psi-mi:“MI:0914”(association)	0.350
CANX	HLA-A	psi-mi:“MI:0914”(association)	0.350
IL17RB	ATP1A3	psi-mi:“MI:0914”(association)	0.350
	IL17RB	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (54): IL17RB (Affinity Capture-Western), SELO (Affinity Capture-MS), RNFT1 (Affinity Capture-MS), TMEM63B (Affinity Capture-MS), PIGQ (Affinity Capture-MS), ATP2A3 (Affinity Capture-MS), BMPR1A (Affinity Capture-MS), STIM1 (Affinity Capture-MS), RETSAT (Affinity Capture-MS), ST7L (Affinity Capture-MS), RHOBTB3 (Affinity Capture-MS), BTN2A2 (Affinity Capture-MS), TYW1 (Affinity Capture-MS), RNF149 (Affinity Capture-MS), MFAP3 (Affinity Capture-MS)

ESM2 similar proteins: A0JPE1, A4D0V7, D3Z2R5, O43916, P97259, Q08834, Q09328, Q1RLQ5, Q3TUA9, Q4V8A9, Q58CX7, Q5F349, Q5FVL3, Q5HZP7, Q5NDE4, Q5NDE5, Q5NDE7, Q5NDE8, Q5R634, Q5R9Q9, Q5RJQ0, Q5T7M9, Q5U3W1, Q5VUD6, Q640M6, Q68CR1, Q6DBY9, Q6DCL6, Q6Q2W4, Q80TS8, Q8C1F4, Q8C3I9, Q8N6G5, Q8NBP0, Q8NHY0, Q8R4G6, Q8R553, Q8WTR4, Q92179, Q95JJ0

Diamond homologs: Q9JIP3, Q9NRM6

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
IL17B	up-regulates	IL17RB	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

56 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	42
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2188 predictions. Top by Δscore:

Variant	Effect	Δscore
3:53846645:GCCG:G	donor_gain	1.0000
3:53851997:A:AG	acceptor_gain	1.0000
3:53851998:G:GG	acceptor_gain	1.0000
3:53851998:GCC:G	acceptor_gain	1.0000
3:53852120:TGGTA:T	donor_gain	1.0000
3:53852127:G:GG	donor_gain	1.0000
3:53852869:A:AG	acceptor_gain	1.0000
3:53852870:G:GA	acceptor_gain	1.0000
3:53858819:G:GG	donor_gain	1.0000
3:53846169:TTA:T	donor_gain	0.9900
3:53846647:CGGT:C	donor_loss	0.9900
3:53846648:GGTAA:G	donor_loss	0.9900
3:53846649:G:A	donor_loss	0.9900
3:53846649:G:GG	donor_gain	0.9900
3:53846650:TAA:T	donor_loss	0.9900
3:53851989:ATCTC:A	acceptor_gain	0.9900
3:53851990:T:G	acceptor_gain	0.9900
3:53851993:C:CA	acceptor_gain	0.9900
3:53851994:GGCA:G	acceptor_loss	0.9900
3:53851995:GCA:G	acceptor_loss	0.9900
3:53851996:CA:C	acceptor_loss	0.9900
3:53851997:A:AC	acceptor_loss	0.9900
3:53851998:G:GA	acceptor_loss	0.9900
3:53851998:GCCA:G	acceptor_gain	0.9900
3:53852121:G:GA	donor_gain	0.9900
3:53852122:GTAAA:G	donor_gain	0.9900
3:53852124:AAAGT:A	donor_loss	0.9900
3:53852125:AAGTA:A	donor_loss	0.9900
3:53852127:GTA:G	donor_loss	0.9900
3:53852128:TAAG:T	donor_loss	0.9900

AlphaMissense

3314 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:53856854:G:C	W180C	0.995
3:53856854:G:T	W180C	0.995
3:53849777:T:A	W70R	0.992
3:53849777:T:C	W70R	0.992
3:53856906:T:C	F198L	0.992
3:53856907:T:C	F198S	0.992
3:53856908:C:A	F198L	0.992
3:53856908:C:G	F198L	0.992
3:53849779:G:C	W70C	0.989
3:53849779:G:T	W70C	0.989
3:53852076:T:A	C102S	0.988
3:53852077:G:C	C102S	0.988
3:53852871:T:A	W119R	0.988
3:53852871:T:C	W119R	0.988
3:53856852:T:A	W180R	0.988
3:53856852:T:C	W180R	0.988
3:53852019:G:C	A83P	0.987
3:53852873:G:C	W119C	0.987
3:53852873:G:T	W119C	0.987
3:53852936:T:A	N140K	0.985
3:53852936:T:G	N140K	0.985
3:53855329:T:A	C173S	0.983
3:53855330:G:C	C173S	0.983
3:53852095:T:G	F108C	0.982
3:53852076:T:C	C102R	0.981
3:53855329:T:C	C173R	0.981
3:53856907:T:G	F198C	0.981
3:53858754:C:G	C261W	0.979
3:53855296:T:A	C162S	0.978
3:53855297:G:C	C162S	0.978

dbSNP variants (sampled 300 via entrez): RS1000007560 (3:53866228 T>TA), RS1000093602 (3:53856803 A>G), RS1000499577 (3:53858135 C>T), RS1000552042 (3:53857914 C>T), RS1000648905 (3:53846022 C>A,G,T), RS1000701076 (3:53846188 C>T), RS1000782666 (3:53862706 T>C), RS1001048319 (3:53846019 T>TC), RS1001064326 (3:53864374 A>G), RS1001111449 (3:53852898 G>A,C), RS1001328332 (3:53860025 TAAAA>T,TAA,TAAA,TAAAAA), RS1001331931 (3:53846245 C>G), RS1001550079 (3:53862461 T>C), RS1001880752 (3:53863771 T>A), RS1001886227 (3:53857473 G>A,C,T)

Disease associations

OMIM: gene MIM:605458 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST002115_6	Axial length	8.000000e-06
GCST005951_50	Body mass index	5.000000e-11
GCST009569_1	interleukin 17 receptor B levels	2.000000e-18
GCST010002_424	Refractive error	9.000000e-24
GCST012081_1	Response to tofacitinib treatment (herpes zoster)	3.000000e-06
GCST012082_1	Response to tofacitinib treatment (herpes zoster)(time to event)	8.000000e-10
GCST012084_2	Response to tofacitinib treatment in rheumatoid arthritis (herpes zoster)	2.000000e-06
GCST012086_2	Response to tofacitinib treatment in rheumatoid arthritis (herpes zoster)(time to event)	3.000000e-07

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0005318	axial length measurement
EFO:0004340	body mass index
EFO:0008176	interleukin 17 receptor B measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — IL-17 receptor family

CTD chemical–gene interactions

52 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	affects binding, increases expression, affects cotreatment, decreases expression	5
Tetrachlorodibenzodioxin	affects expression, affects cotreatment, increases expression	5
Cyclosporine	decreases expression	4
Valproic Acid	affects expression, decreases expression, increases expression	3
Zoledronic Acid	decreases expression	2
Benzo(a)pyrene	affects methylation, increases expression	2
Coumestrol	increases expression, affects reaction, affects cotreatment	2
Progesterone	affects cotreatment, decreases expression	2
bisphenol A	affects expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
beta-lapachone	decreases expression	1
methylparaben	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
3,4,5,3’,4’-pentachlorobiphenyl	increases expression	1
doxifluridine	increases response to substance	1
1-UFT protocol	increases response to substance	1
butylparaben	increases expression	1
2,3-dimethoxy-1,4-naphthoquinone	decreases expression	1
CGP 52608	affects binding, increases reaction	1
perfluoro-n-nonanoic acid	decreases expression	1
entinostat	decreases expression	1
K 7174	decreases expression	1
belinostat	decreases expression	1
(+)-JQ1 compound	decreases expression	1
Capecitabine	increases response to substance	1
Resveratrol	affects cotreatment, increases expression	1
Temozolomide	increases expression	1
Sunitinib	decreases expression	1
Fulvestrant	affects cotreatment, decreases expression	1
Troglitazone	decreases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B7XP	Abcam Raji IL17RB KO	Cancer cell line	Male
CVCL_B9YD	Abcam THP-1 IL17RB KO	Cancer cell line	Male
CVCL_C7A6	Abcam PC-3 IL17RB KO	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.